171 related articles for article (PubMed ID: 30643946)
1. Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.
Bonatti M; Valletta R; Zamboni GA; Lombardo F; Senoner M; Simioni M; Schifferle G; Bonatti G
Eur Radiol; 2019 Jun; 29(6):2830-2836. PubMed ID: 30643946
[TBL] [Abstract][Full Text] [Related]
2. Liver enhancement during hepatobiliary phase after Gd-BOPTA administration: correlation with liver and renal function.
Bonatti M; Valletta R; Avesani G; Lombardo F; Cannone F; Zamboni GA; Mansueto G; Manfredi R; Ferro F
Eur Radiol; 2021 Apr; 31(4):2490-2496. PubMed ID: 33000303
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents.
Ciolina M; Di Martino M; Bruno O; Pommier R; Vilgrain V; Ronot M
Eur Radiol; 2018 Jul; 28(7):3020-3031. PubMed ID: 29374320
[TBL] [Abstract][Full Text] [Related]
4. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
[TBL] [Abstract][Full Text] [Related]
5. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
[TBL] [Abstract][Full Text] [Related]
7. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
Yeom SK; Byun JH; Kim HJ; Park SH; Kim N; Shin YM; Kim PN
Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
[TBL] [Abstract][Full Text] [Related]
8. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
[TBL] [Abstract][Full Text] [Related]
9. Intrahepatic mass-forming cholangiocarcinoma: enhancement pattern on Gd-BOPTA-MRI with emphasis of hepatobiliary phase.
Mamone G; Marrone G; Caruso S; Carollo V; Gentile G; Crino' F; Milazzo M; Luca A
Abdom Imaging; 2015 Oct; 40(7):2313-22. PubMed ID: 25962708
[TBL] [Abstract][Full Text] [Related]
10. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis.
Li XM; Chen Z; Xiao EH; Shang QL; Ma C
World J Gastroenterol; 2017 May; 23(17):3133-3141. PubMed ID: 28533670
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
[TBL] [Abstract][Full Text] [Related]
13. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
Grazioli L; Morana G; Kirchin MA; Caccia P; Romanini L; Bondioni MP; Procacci C; Chiesa A
J Magn Reson Imaging; 2003 May; 17(5):593-602. PubMed ID: 12720270
[TBL] [Abstract][Full Text] [Related]
14. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
[TBL] [Abstract][Full Text] [Related]
15. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
16. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
Grazioli L; Morana G; Caudana R; Benetti A; Portolani N; Talamini G; Colombari R; Pirovano G; Kirchin MA; Spinazzi A
Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
[TBL] [Abstract][Full Text] [Related]
18. Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors.
Lewis S; Vasudevan P; Chatterji M; Besa C; Jajamovich G; Facciuto M; Taouli B
Abdom Radiol (NY); 2016 Jul; 41(7):1300-9. PubMed ID: 26960727
[TBL] [Abstract][Full Text] [Related]
19. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.
Schneider G; Maas R; Schultze Kool L; Rummeny E; Gehl HB; Lodemann KP; Kirchin MA
Invest Radiol; 2003 Feb; 38(2):85-94. PubMed ID: 12544071
[TBL] [Abstract][Full Text] [Related]
20. Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure.
Liu C; Shen Z; Ma H; Wang X; Wang X; Liu K; Wang X; Zhu Q; Zhao X
Eur Radiol; 2022 May; 32(5):3006-3015. PubMed ID: 34989839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
